UVA-1 therapy for sclerosing skin disease: A pilot study of patient and clinician-reported outcomes in a single-arm nonrandomized trial
Christiaan H. Noot, Zachary Hopkins, Mason M. Seely, Rachel M. Seifert, Laurel Gray, Vikram Sahni, Amber Jimenez, Aaron Secrest, Christopher B. Hansen · 2026
Read UVA-1 therapy for sclerosing skin disease: A pilot study of patient and clinician-reported outcomes in a single-arm nonrandomized trial by Christiaan H. Noot, Zachary Hopkins, Mason M. Seely, Rachel M. Seifert, Laurel Gray, Vikram Sahni, Amber Jimenez, Aaron Secrest, Christopher B. Hansen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427491.txt.
Description
Christiaan H. Noot and coauthors piloted UVA-1 light therapy for sclerosing skin diseases in a 2026 single-arm nonrandomized study at the University of Utah. These inflammatory connective tissue diseases thicken and scar skin, hurt quality of life, and resist standard topical, injected, and systemic immune treatments. Seventeen adults completed thirty sessions of UVA-1 at 50 to 90 joules per square centimeter within one hundred days, averaging two to three sessions weekly.
Both patient-reported and clinician-reported outcomes were tracked to judge benefit from the skin's perspective and the examiner's. Pilot evidence for phototherapy in this stubborn disease group can justify a randomized trial.
Catalog record
| CREATOR | Christiaan H. Noot, Zachary Hopkins, Mason M. Seely, Rachel M. Seifert, Laurel Gray, Vikram Sahni, Amber Jimenez, Aaron Secrest, Christopher B. Hansen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7869 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |